186 related articles for article (PubMed ID: 27256098)
21. Results of a prospective multicenter neuroendocrine tumor registry reporting on clinicopathologic characteristics of Greek patients.
Nikou GC; Pazaitou-Panayiotou K; Dimitroulopoulos D; Alexandrakis G; Papakostas P; Vaslamatzis M; Kaldrymidis P; Markussis V; Koumarianou A;
BMC Endocr Disord; 2016 Feb; 16():8. PubMed ID: 26872616
[TBL] [Abstract][Full Text] [Related]
22. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
[TBL] [Abstract][Full Text] [Related]
23. Decoding the Molecular and Mutational Ambiguities of Gastroenteropancreatic Neuroendocrine Neoplasm Pathobiology.
Kidd M; Modlin IM; Bodei L; Drozdov I
Cell Mol Gastroenterol Hepatol; 2015 Mar; 1(2):131-153. PubMed ID: 28210673
[TBL] [Abstract][Full Text] [Related]
24. Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin.
Saller JJ; Haider M; Al-Diffalha S; Coppola D
Anticancer Res; 2022 Mar; 42(3):1381-1396. PubMed ID: 35220231
[TBL] [Abstract][Full Text] [Related]
25. Loss of PTEN and Increased pAKT Expression Distinguishes Aggressive Low-grade Neuroendocrine Tumors.
Jayakumar R; Lanjewar S; Axiotis CA
Ann Clin Lab Sci; 2018 Sep; 48(5):565-572. PubMed ID: 30373859
[TBL] [Abstract][Full Text] [Related]
26. Frequency and characterization of gastro-entero-pancreatic neuroendocrine tumor patients with high-grade of uptake at somatostatin receptor scintigraphy.
Chougnet CN; Leboulleux S; Caramella C; Lumbroso J; Borget I; Déandreis D; Duvillard P; Elias D; de Baere T; Vélayoudom-Céphise FL; Guigay J; Ducreux M; Schlumberger M; Baudin E
Endocr Relat Cancer; 2013 Apr; 20(2):229-39. PubMed ID: 23404855
[TBL] [Abstract][Full Text] [Related]
27. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors.
O'Toole D; Couvelard A; Rebours V; Zappa M; Hentic O; Hammel P; Levy P; Bedossa P; Raymond E; Ruszniewski P
Endocr Relat Cancer; 2010 Dec; 17(4):847-56. PubMed ID: 20570957
[TBL] [Abstract][Full Text] [Related]
28. Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors?
Körner M; Waser B; Reubi JC
Neuroendocrinology; 2015; 101(1):45-57. PubMed ID: 25591947
[TBL] [Abstract][Full Text] [Related]
29. The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant.
Modlin IM; Moss SF; Gustafsson BI; Lawrence B; Schimmack S; Kidd M
Langenbecks Arch Surg; 2011 Dec; 396(8):1145-56. PubMed ID: 21523447
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the expression of somatostatin receptors by immunohistochemistry in neuroendocrine tumors of the small intestine.
Pol J Pathol; 2020; 71(1):30-37. PubMed ID: 32429652
[TBL] [Abstract][Full Text] [Related]
31. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
32. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
[TBL] [Abstract][Full Text] [Related]
33. PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases.
Wang LL; Hao S; Zhang S; Guo LJ; Hu CY; Zhang G; Gao B; Zhao JJ; Jiang Y; Tian WG; Wang J; Luo DL
Hum Pathol; 2017 Mar; 61():49-57. PubMed ID: 27864123
[TBL] [Abstract][Full Text] [Related]
34. Progesterone receptor and PTEN expression predict survival in patients with low- and intermediate-grade pancreatic neuroendocrine tumors.
Estrella JS; Broaddus RR; Mathews A; Milton DR; Yao JC; Wang H; Rashid A
Arch Pathol Lab Med; 2014 Aug; 138(8):1027-36. PubMed ID: 25076292
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
36. Analysis of miR-96 and miR-133a Expression in Gastrointestinal Neuroendocrine Neoplasms.
Mandal R; Hardin H; Baus R; Rehrauer W; Lloyd RV
Endocr Pathol; 2017 Dec; 28(4):345-350. PubMed ID: 29032398
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms.
Briest F; Wang Y; Arsenic R; Elezkurtaj S; Berg E; Greshake S; Lock AC; Hörsch D; Arnold CN; Hummel M; Siegmund B; Grabowski P
Anticancer Res; 2018 Jul; 38(7):3863-3870. PubMed ID: 29970506
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
[TBL] [Abstract][Full Text] [Related]
39. Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms.
Panzuto F; Cicchese N; Partelli S; Rinzivillo M; Capurso G; Merola E; Manzoni M; Pucci E; Iannicelli E; Pilozzi E; Rossi M; Doglioni C; Falconi M; Delle Fave G
PLoS One; 2017; 12(6):e0179445. PubMed ID: 28644861
[TBL] [Abstract][Full Text] [Related]
40. Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer.
Terlević R; Perić Balja M; Tomas D; Skenderi F; Krušlin B; Vranic S; Demirović A
Ann Diagn Pathol; 2019 Feb; 38():62-66. PubMed ID: 30476894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
